
Uwe Platzbecker
Articles
-
Feb 21, 2025 |
nature.com | Maximilian Merz |David Fandrei |Eva Heger |Viola Schweinsberg |Uwe Platzbecker |Michael Hallek | +3 more
AbstractChimeric antigen receptor (CAR) T cells and bispecific T cell engagers have become integral components in the treatment of relapsed/refractory multiple myeloma. We report a 63-year-old male who received ciltacabtagene autoleucel CAR T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. Nine months after CAR T therapy, he developed a symptomatic leukemic peripheral T cell lymphoma with cutaneous and intestinal involvement.
-
Dec 4, 2024 |
nature.com | Sarah Flossdorf |Sandra Sauer |Hartmut Goldschmidt |Monika Engelhardt |Robert Zeiser |Vladan Vucinic | +5 more
AbstractIdentifying patients who may benefit from autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma is crucial, especially in the era of effective induction and consolidation strategies. We analyzed data from 12763 patients enrolled in the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST), distinguishing those who underwent single (n = 8736) or tandem ASCT (n = 4027) from 1998 to 2021.
-
Jul 31, 2024 |
onclive.com | Uwe Platzbecker
CommentaryVideoJuly 31, 2024Author(s):Uwe Platzbecker, MD, discusses efficacy data with the combination of all-trans retinoic acid and arsenic trioxide in high-risk acute promyelocytic leukemia.
-
Jan 6, 2024 |
nature.com | Anne Sophie Kubasch |Song Wang |Sebastian Schwind |Klaus H. Metzeler |Madlen Jentzsch |Kristin Reiche | +2 more
AbstractB-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T cells revolutionized the treatment of relapsed/refractory multiple myeloma (RRMM). However, data on cellular (CAR) T cell dynamics and the association with response, resistance or the occurrence of cytokine release syndrome (CRS) are limited.
-
Dec 14, 2023 |
sciencedirect.com | Uwe Platzbecker |Amer M Zeidan
There are more references available in the full text version of this article.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →